PORTON BIOPHARMA LIMITED (09331560) is a private limited company registered in SALISBURY, incorporated in 2014. The company operates in the manufacture of pharmaceutical preparations sector. Our database holds 29 signals from 14 official sources covering this company's filings, appointments, and regulatory records. Risk assessment: 90/100 ("robust"), reflecting a strong compliance and financial profile.
Porton Biopharma Limited is an active private company incorporated in 2014 based in Salisbury, operating within the pharmaceutical preparations manufacturing industry. The company develops and manufactures life-saving products, specifically citing the Erwinase Anthrax Vaccine, while employing in-house processes for production and quality regulation.
Standard data coverage across 14 sources. Risk score of 90 indicates a strong compliance profile.
PORTON BIOPHARMA LIMITED is 1 of 1 manufacture of pharmaceutical preparations companies in SALISBURY, out of 519 active companies in this sector nationally (631 including dissolved).
PORTON BIOPHARMA LIMITED is listed as the proprietor of 1 property in the HM Land Registry.
Properties are located in South West.
PORTON BIOPHARMA LIMITED has been awarded 1 government contract with a combined value of £13K.
The most recent contract was with UKHSA (23 Dec 2024).
PORTON BIOPHARMA LIMITED has received 1 Innovate UK grant.
This company profile is built from 13 official data sources: Ch Officers, Companies House, Contracts Finder, Environment Agency, Gateway to Research, Gender Pay Gap Service, HM Land Registry, HMRC Trade Info, ICO, Innovate UK, Modern Slavery Registry, Uk Trade Info, WHOIS.
Porton Biopharma Limited is an active private company incorporated in 2014 based in Salisbury, operating within the pharmaceutical preparations manufacturing industry.
Current directors include MR ANDREW JAMES SEBASTIAN BURN, MR ALEX JONES, MR RICHARD PAUL SMITH.
PORTON BIOPHARMA LIMITED is registered in SALISBURY, United Kingdom.
PORTON BIOPHARMA LIMITED operates under SIC code 21200 — Manufacture of pharmaceutical preparations.
PORTON BIOPHARMA LIMITED has a risk score of 90 out of 100, classified as "Robust". This score is calculated from 29 data signals across 14 government sources.
The next accounts for PORTON BIOPHARMA LIMITED are due on 30 Jun 2027.
PORTON BIOPHARMA LIMITED offers Erwinase, Anthrax Vaccine, Biopharmaceutical therapeutics, Vaccines.
Yes, PORTON BIOPHARMA LIMITED is listed as the proprietor of 1 property in the HM Land Registry, located in South West.
Yes, PORTON BIOPHARMA LIMITED has been awarded 1 government contract with a combined value of £13K.
The dissolution rate for the manufacture of pharmaceutical preparations sector in the UK is 12%. The average company age in this sector is 13.1 years.
PORTON BIOPHARMA LIMITED is currently listed as "Active" on Companies House, indicating it is still a registered company. An "Active" status means the company has not been dissolved, struck off, or entered into liquidation.
PORTON BIOPHARMA LIMITED is registered as a Private Limited Company, which is a company limited by shares whose shares are not offered to the general public. It is the most common type of UK company, offering limited liability to its shareholders.
PORTON BIOPHARMA LIMITED was incorporated on 27 Nov 2014, making it 12 years old. The company remains active and in good standing.
PORTON BIOPHARMA LIMITED is classified under SIC code 21200 (Manufacture of pharmaceutical preparations). The Standard Industrial Classification system is used by the UK government to categorise businesses by their primary economic activity.
We track 29 data signals from 14 official government sources for PORTON BIOPHARMA LIMITED.